非小细胞肺癌（NSCLC）基因变异概览和靶向治疗发展史【前沿资讯】

联川生物 2022-05-21

The following article is from 联川基因 Author Luanne

引言

2018 CA Cancer发布全球范围内癌症统计数据显示肺癌仍是目前癌症死亡的主要原因。非小细胞肺癌（non-small cell lung cancer, NSCLC）约占肺癌的85%。腺癌（adenocarcinoma, AC）、鳞状细胞癌（squamous cell carcinoma, SCC）是NSCLC最常见的两种病理类型，其中AC和SCC约占70%。

随着分子诊断技术的不断发展，尤其NGS技术的极速推广，更多的驱动基因被发现。针对EGFR, ALK, ROS1,RET, BRAF, MET, HER2, NTRK基因变异的诸多靶向药物已被NCCN推荐临床使用。但靶向治疗面临的一个很大问题是耐药的产生，了解靶药的作用机制及耐药机制，对于新一代药物的开发或其他治疗模式的思考是具有重要意义的。

参考文献

1.<非小细胞肺癌组织中+ALK、ROS1和+RET融合基因的表达及其临床意义.pdf>.

2.Williams, H.L., etal., Validation of the Oncomine™ focuspanel for next-generation sequencing of clinical tumour samples. VirchowsArchiv, 2018. 473(4): p. 489-503.

3.Xu, L., et al., [Clinical significance of ROS1rearrangements in non-small cell lung cancer]. Zhongguo fei ai za zhi =Chinese journal of lung cancer, 2013. 16(12):p. 663-670.

4.Schram, A.M., etal., Fusions in solid tumours: diagnosticstrategies, targeted therapy, and acquired resistance. Nature ReviewsClinical Oncology, 2017. 14: p. 735.

5.Hirsch, F.R., etal., Lung cancer: current therapies andnew targeted treatments. Lancet, 2017. 389(10066):p. 299-311.

6.Reck, M. and K.F.Rabe, Precision Diagnosis and Treatmentfor Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(9): p. 849-861.

7.Herbst, R.S., D.Morgensztern, and C. Boshoff, The biologyand management of non-small cell lung cancer. Nature, 2018. 553(7689): p. 446-454.

8.Cocco, E., M.Scaltriti, and A. Drilon, NTRKfusion-positive cancers and TRK inhibitor therapy. Nature Reviews ClinicalOncology, 2018. 15(12): p. 731-747.

9.Farago, A.F. andC.G. Azzoli, Beyond ALK and ROS1: RET,NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.Transl Lung Cancer Res, 2017. 6(5):p. 550-559.

10.Kohno, T., et al., Beyond ALK-RET, ROS1 and other oncogenefusions in lung cancer. Transl Lung Cancer Res, 2015. 4(2): p. 156-64.

11.Velizheva, N.P., etal., Targeted next-generation-sequencingfor reliable detection of targetable rearrangements in lung adenocarcinoma-asingle center retrospective study. Pathol Res Pract, 2018. 214(4): p. 572-578.

12.Ferrara, R., et al.,Clinical and Translational Implicationsof RET Rearrangements in Non-Small Cell Lung Cancer. J Thorac Oncol, 2018. 13(1): p. 27-45.

13.Rogers, T.-M., etal., Multiplexed transcriptome analysisto detect ALK, ROS1 and RET rearrangements in lung cancer. ScientificReports, 2017. 7: p. 42259.

14.Gou, L.-Y. and Y.-L.Wu, Prevalence of driver mutations innon-small-cell lung cancers in the People's Republic of China. Lung Cancer(Auckland, N.Z.), 2014. 5: p. 1-9.

15.Asao, T., F.Takahashi, and K. Takahashi, Resistanceto molecularly targeted therapy in non-small-cell lung cancer. RespirInvestig, 2019. 57(1): p. 20-26.

16.Rotow, J. and T.G.Bivona, Understanding and targetingresistance mechanisms in NSCLC. Nat Rev Cancer, 2017. 17(11): p. 637-658.

17.Du, X., et al., ALK-rearrangement in non-small-cell lungcancer (NSCLC). Thorac Cancer, 2018. 9(4):p. 423-430.

18.Kerr, K.M. and F.Lopez-Rios, Precision medicine in NSCLCand pathology: how does ALK fit in the pathway? Ann Oncol, 2016. 27 Suppl 3: p. iii16-iii24.

19.Rossi, G., et al., Detection of ROS1 rearrangement in non-smallcell lung cancer: current and future perspectives. Lung Cancer (Auckl),2017. 8: p. 45-55.

20.Bubendorf, L., etal., Testing for ROS1 in non-small celllung cancer: a review with recommendations. Virchows Arch, 2016. 469(5): p. 489-503.

未完待续~~~

今天的分享就到这里，下一期将为大家带来下篇：非小细胞肺癌中的融合基因。

需要原文及更多癌种靶向药介绍的小伙伴可以留言给我们哦，小编会尽快发送资料给您~

留言方式：邮箱+电话+NSCLC

VariantBaits™ Target Enrichment System

液相杂交捕获系统

基于自主知识产权μParaﬂo® 微流体芯片平台合成RNA捕获探针，采用液相杂交技术捕获靶标DNA，使用生物素标记探针诱饵，探针序列与靶向序列互补，完成靶向序列文库的富集与制备。可用于从小到大规模的基因捕获，容忍某些局部模板的变异。

VariantPro™ One-Step Multiplex PCR System

一步式多重PCR建库系统

经过LC Sciences科学家两年潜心攻关，于2015年成功研发出VariantPro™一步式多重PCR建库系统，在目标区域进行引物设计，通过多重PCR的方式进行目标区域扩增，通常不受引物间模板变异的影响。文库制备可简化成一步，人工操作时间仅5分钟，可用于小到中规模的基因捕获。

了解更多基因捕获技术信息，关注“联川基因”公众号，回复“双V捕获”即可获得。